Stem cell factor 248 shapes ILC2 transcriptional programs and promotes mucosal inflammation in allergic asthma - Top-Institutions - MDSpire

Stem cell factor 248 shapes ILC2 transcriptional programs and promotes mucosal inflammation in allergic asthma

  • By

  • Nobuhiro Asai

  • Grace K. Lombardo

  • Ramon Ocadiz-Ruiz

  • Yao Gu

  • Andrew J. Rasky

  • Dana S. Garcia

  • Angela J. Montoya

  • Sarita Montaño

  • Kazuma Yagi

  • Wendy Fonseca

  • July 2, 2026

  • 0 min

Share

Top Institutions in Pulmonary

Brief introduction explaining scope and methodology.

  • #1

    University of Michigan Medical School
    University of Michigan Medical School

    Ann Arbor, Michigan

    Key Differentiators

    • Allergy and Immunology

  • #2

    UCSF Health / University of California, San Francisco
    UCSF Health / University of California, San Francisco

    San Francisco, California

    Key Differentiators

    • Allergy and Immunology

  • #3

    Osaka University School of Medicine
    Osaka University School of Medicine

    Osaka, Japan

    Key Differentiators

    • Allergy and Immunology

  • #4

    Hyogo Medical University
    Hyogo Medical University

    Hyogo, Japan

    Key Differentiators

    • Allergy and Immunology

  • #5

    Hannover Medical School
    Hannover Medical School

    Hannover, Germany

    Key Differentiators

    • Allergy and Immunology

Original Source(s)

Stem cell factor 248 shapes ILC2 transcriptional programs and promotes mucosal inflammation in allergic asthma

  • by Nobuhiro Asai, Grace K. Lombardo, Ramon Ocadiz-Ruiz, Yao Gu, Andrew J. Rasky, Dana S. Garcia, Angela J. Montoya, Sarita Montaño, Kazuma Yagi, Wendy Fonseca

  • July 2, 2026

Related Content

When Bad Data Enters the Drug Pipeline

Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.

From anaphylaxis to eosinophilic esophagitis during omalizumab treatment in a boy with severe asthma and food allergy: a case report

FDA Expands Afrezza to Pediatric Diabetes

The decision was supported by the phase 3 INHALE-1 trial and additional long-term safety, efficacy, and exposure data.